Anormed Ord (MM) News - ANOR

AnorMED board continues to recommend that shareholders accept Millennium's planned tender offer

AnorMED determines that new Genzyme proposal could lead to superior offer VANCOUVER, Oct. 4 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR;...

Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date

Phase III MOZOBIL complements Millennium's market-leading VELCADE and enhances patient eligibility for potentially life-saving stem cell...

AnorMED agrees to support a planned tender offer of US$12 per share from Millennium Pharmaceuticals

VANCOUVER, Sept. 26 /PRNewswire-FirstCall/ -- AnorMED Inc. ( NASDAQ:ANOR; TSX: AOM) today announced its Board of Directors has entered into a...

Approval of FOSRENOL in the United Kingdom triggers U.S.$3 million payment to AnorMED

VANCOUVER, Sept. 25 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that under the terms of an existing agreement...

AnorMED reports on Annual General Meeting

VANCOUVER, Sept. 20 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) announced yesterday at its Annual...

Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Cond

Agreement Eliminates Development Milestones, Significantly Reduces Royalties and Restructures Sublicense Provisions SOUTH SAN FRANCISCO, Calif...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Anormed Ord (MM) (ANOR)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ANOR News

AnorMED board continues to recommend that shareholders accept Millennium's planned tender offer

Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date

AnorMED agrees to support a planned tender offer of US$12 per share from Millennium Pharmaceuticals

Approval of FOSRENOL in the United Kingdom triggers U.S.$3 million payment to AnorMED

AnorMED reports on Annual General Meeting

Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Cond

Approval of FOSRENOL in Germany triggers U.S.$3 million payment to AnorMED

AnorMED Provides Update on Limited Duration Shareholder Rights Plan

Atticus Capital LP Opposes Genzyme bid for AnorMED

ANOR Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Anormed Ord (MM) (ANOR) News

Anormed Ord (MM) (ANOR)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ANOR News

AnorMED board continues to recommend that shareholders accept Millennium's planned tender offer

Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date

AnorMED agrees to support a planned tender offer of US$12 per share from Millennium Pharmaceuticals

Approval of FOSRENOL in the United Kingdom triggers U.S.$3 million payment to AnorMED

AnorMED reports on Annual General Meeting

Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Cond

Approval of FOSRENOL in Germany triggers U.S.$3 million payment to AnorMED

AnorMED Provides Update on Limited Duration Shareholder Rights Plan

Atticus Capital LP Opposes Genzyme bid for AnorMED

ANOR Discussion

Your Recent History